Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Army
AstraZeneca
Cipla
Merck
McKinsey
Harvard Business School
Argus Health
Novartis
Citi

Generated: February 25, 2018

DrugPatentWatch Database Preview

ORAP Drug Profile

« Back to Dashboard

When do Orap patents expire, and what generic alternatives are available?

Orap is a drug marketed by Teva and Concordia Pharms Inc and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ORAP is prednisolone sodium phosphate. There are eighty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

US Patents and Regulatory Information for ORAP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva ORAP pimozide TABLET;ORAL 017473-003 Aug 27, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Teva ORAP pimozide TABLET;ORAL 017473-001 Jul 31, 1984 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Concordia Pharms Inc ORAPRED prednisolone sodium phosphate SOLUTION;ORAL 075117-001 Dec 14, 2000 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ORAP
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Orally Disintegrating Tablets 10 mg, 15 mg and 30 mg ➤ Subscribe 7/22/2010

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
US Army
Queensland Health
Daiichi Sankyo
UBS
Teva
Chubb
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot